The CTRB2 misfolding variant refers to a genetic alteration involving the deletion of exon 6 in the CTRB2 gene, which encodes a protein called chymotrypsinogen B2. This variant has been linked to an increased risk of pancreatic cancer due to its effects on protein folding and cellular stress.
The CTRB2 misfolding variant refers to a genetic alteration involving the deletion of exon 6 in the CTRB2 gene, which encodes a protein called chymotrypsinogen B2. This variant has been linked to an increased risk of pancreatic cancer due to its effects on protein folding and cellular stress. Research using a CRISPR/Cas9-engineered mouse model that mimics this human genetic variant has shown that the mutation causes the production of a truncated version of another related protein, CTRB1. This misfolded protein accumulates in the endoplasmic reticulum (ER), leading to ER stress and the formation of protein inclusions.
The resulting ER stress disrupts normal pancreatic cell function, reducing chymotrypsin enzyme activity, protein synthesis, and secretion of digestive enzymes like amylase. Additionally, it activates inflammatory pathways and impairs the pancreas's ability to recover from injury, creating a pro-inflammatory and pro-cancer environment in the pancreas. This microenvironment increases the risk of developing pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer.
While this discovery highlights the potential of the CTRB2 variant as a marker for identifying individuals at higher risk of pancreatic cancer, routine genetic testing is not yet recommended. However, future strategies combining ER stress-relieving drugs and anti-inflammatory treatments may help mitigate this risk.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.